Understanding diabetes
Diabetes mellitus is a group of metabolic diseases characterized by chronically elevated blood glucose (hyperglycemia). To understand what goes wrong, you first need to understand insulin — the key that unlocks your cells to allow glucose in.
When you eat carbohydrates, your digestive system breaks them down into glucose, which enters your bloodstream. Your pancreas — specifically the beta cells in the islets of Langerhans — detects rising blood sugar and releases insulin. Insulin acts like a key, binding to receptors on cells throughout your body and allowing glucose to enter and be used for energy or stored as glycogen.
In diabetes, this system breaks down in one of two fundamental ways: either the pancreas produces little or no insulin (Type 1), or cells throughout the body stop responding normally to insulin — known as insulin resistance — and the pancreas can't produce enough to compensate (Type 2).
Without adequate insulin action, glucose accumulates in the bloodstream. Over time, this persistent hyperglycemia damages blood vessels and nerves throughout the body — leading to the devastating complications that make diabetes one of the leading causes of blindness, kidney failure, amputation, and cardiovascular disease worldwide.
HbA1c (glycated hemoglobin) measures the percentage of hemoglobin molecules in your red blood cells that have glucose attached to them. Because red blood cells live for about 3 months, HbA1c reflects your average blood sugar over the preceding 2–3 months — giving doctors a far more meaningful picture than a single fasting glucose measurement. A normal HbA1c is below 5.7%; prediabetes is 5.7–6.4%; diabetes is 6.5% or above. For most people with diabetes, the treatment target is below 7.0%, though targets may be individualized based on age, comorbidities, and risk of hypoglycemia.
Types of diabetes
Type 1
- Autoimmune destruction of beta cells
- 5–10% of all diabetes cases
- Often onset in childhood/young adulthood
- Requires lifelong insulin
- Not preventable
- Strong genetic component
Type 2
- Insulin resistance + beta cell dysfunction
- 90–95% of all cases
- Typically adult onset (but rising in youth)
- Managed with lifestyle, oral drugs, +/- insulin
- Largely preventable; can enter remission
- Strongly linked to obesity, inactivity
Gestational
- Develops during pregnancy
- ~7–10% of all pregnancies
- Usually resolves post-delivery
- Managed with diet, sometimes insulin
- Increases T2D risk later in life
- Risks to baby if uncontrolled
LADA
- Latent Autoimmune Diabetes in Adults
- "Type 1.5" — often misdiagnosed as T2
- Slower beta cell destruction
- Initially responds to oral meds
- Eventually requires insulin
- GAD antibody test confirms diagnosis
Prediabetes: the critical window
Prediabetes affects 96 million American adults — roughly 1 in 3 — and the vast majority don't know they have it. Defined as fasting glucose 100–125 mg/dL or HbA1c 5.7–6.4%, prediabetes means your blood sugar is elevated but not yet in the diabetic range.
This is the critical intervention window. Research from the landmark Diabetes Prevention Program (DPP) showed that intensive lifestyle intervention (7% weight loss + 150 minutes/week of physical activity) reduced progression to Type 2 diabetes by 58% over 3 years — far superior to metformin (31% reduction). With the right intervention, prediabetes does not have to become diabetes.
Symptoms and warning signs
The classic triad of diabetes symptoms reflects the body's response to high blood sugar: glucose spills into the urine, pulling water with it (causing frequent urination and thirst), and cells starved of glucose despite high blood levels signal hunger and trigger fat and muscle breakdown (causing weight loss).
| Symptom | Why it happens | Type 1 prevalence | Type 2 prevalence |
|---|---|---|---|
| Excessive thirst (polydipsia) | Dehydration from glucose-driven urination | Very common | Common |
| Frequent urination (polyuria) | Kidneys flush excess glucose in urine | Very common | Common |
| Unexplained weight loss | Body breaks down fat and muscle for fuel | Very common | Less common |
| Extreme fatigue | Cells can't access glucose for energy | Common | Common |
| Blurred vision | High glucose changes fluid balance in lens | Common | Common |
| Slow-healing wounds | Impaired immune function and circulation | Moderate | Common |
| Frequent infections | High glucose promotes bacterial growth | Moderate | Common |
| Tingling/numbness (hands, feet) | Nerve damage from hyperglycemia | If uncontrolled | Common (often first sign) |
| Darkened skin (acanthosis nigricans) | Sign of insulin resistance | Absent | Common in neck, armpits |
Type 2 diabetes typically develops over years with minimal symptoms. By the time of diagnosis, up to 50% of patients already have evidence of complications — retinopathy, neuropathy, or kidney disease. This is why the American Diabetes Association recommends screening everyone aged 35–70 who is overweight or obese, and earlier in those with additional risk factors.
Diabetic emergencies: know these signs
DKA (Diabetic Ketoacidosis): Nausea, vomiting, abdominal pain, fruity breath, rapid breathing, confusion — mainly Type 1. Severe hypoglycemia: Seizure, unconsciousness, or inability to self-treat low blood sugar — any type on insulin or sulfonylureas.
Diagnosis and screening
ADA diagnostic criteria
| Test | Normal | Prediabetes | Diabetes |
|---|---|---|---|
| Fasting plasma glucose | <100 mg/dL | 100–125 mg/dL | ≥126 mg/dL |
| HbA1c | <5.7% | 5.7–6.4% | ≥6.5% |
| 2-hr glucose (OGTT) | <140 mg/dL | 140–199 mg/dL | ≥200 mg/dL |
| Random glucose + symptoms | — | — | ≥200 mg/dL |
A diagnosis of diabetes requires two abnormal results on separate occasions (unless the patient has classic symptoms with a random glucose ≥200 mg/dL, which is sufficient). HbA1c and fasting glucose are preferred for screening because they require no special preparation beyond overnight fasting.
Who should be screened?
- All adults aged 35–70 who are overweight (BMI ≥25) — every 3 years if normal
- Adults of any age with BMI ≥25 plus any risk factor (family history, high-risk ethnicity, hypertension, dyslipidemia, PCOS, prior gestational diabetes, physical inactivity)
- Asian Americans: screen at BMI ≥23 due to higher metabolic risk at lower BMI
- Children with overweight/obesity plus two or more risk factors
- All pregnant women: screen for gestational diabetes between 24–28 weeks
Complications of diabetes
Chronic hyperglycemia damages blood vessels in two ways. Microvascular complications arise from damage to small vessels — affecting the eyes (retinopathy), kidneys (nephropathy), and nerves (neuropathy). Macrovascular complications arise from accelerated atherosclerosis in large vessels — causing heart attack, stroke, and peripheral artery disease. People with diabetes have a 2–4× higher risk of cardiovascular events than the general population.
| Complication | Mechanism | Prevalence | Prevention |
|---|---|---|---|
| Diabetic retinopathy | Small vessel damage in retina | #1 cause of blindness in working-age adults | Annual eye exams; tight glucose + BP control |
| Diabetic nephropathy | Glomerular damage from hyperglycemia | #1 cause of end-stage renal disease in U.S. | ACE inhibitors/ARBs; SGLT2 inhibitors strongly protective |
| Diabetic neuropathy | Nerve damage from glucose toxicity | ~50% of people with diabetes | Glucose control; foot care; pain management |
| Diabetic foot / amputation | Neuropathy + vascular disease | ~100,000 amputations/year in U.S. | Daily foot inspection; podiatry care; footwear |
| Cardiovascular disease | Accelerated atherosclerosis | Leading cause of death in T2D | GLP-1/SGLT2 drugs; statins; BP control; lifestyle |
| Cognitive decline | Vascular + metabolic brain effects | 2× higher dementia risk | Glucose control; cardiovascular risk management |
Treatment: medications
Treatment strategy differs fundamentally between Type 1 (always requires insulin) and Type 2 (progressive approach starting with lifestyle, adding medications as needed).
Type 1 diabetes requires insulin replacement therapy — there is no alternative. The goal is to mimic the normal physiological pattern of insulin secretion: a low background (basal) level plus mealtime (bolus) spikes.
- Basal-bolus regimen: Multiple daily injections (MDI) — long-acting basal insulin once or twice daily plus rapid-acting insulin at each meal. Flexible and effective when patients are trained in carbohydrate counting and dose adjustment.
- Insulin pump (CSII): Continuous subcutaneous insulin infusion via a small pump worn on the body. Delivers programmable basal rates and mealtime boluses with greater precision than injections.
- Closed-loop / Artificial Pancreas: Insulin pump linked to a continuous glucose monitor (CGM) via an algorithm that automatically adjusts insulin delivery in real time. The most advanced systems (e.g., Omnipod 5, Tandem Control-IQ) reduce hypoglycemia and improve time-in-range dramatically. This represents the current frontier of T1D management.
- Adjunct therapy: Some T1D patients benefit from adding a GLP-1 or SGLT2 inhibitor to reduce insulin doses and provide additional cardiovascular/metabolic benefits — though requires careful monitoring for DKA risk with SGLT2 inhibitors.
| Drug class | Key examples | HbA1c reduction | Weight effect | Key benefit |
|---|---|---|---|---|
| Metformin | Glucophage | 1–1.5% | Neutral / mild loss | First-line; inexpensive; CV-neutral; reduces DM risk |
| GLP-1 receptor agonists | Semaglutide (Ozempic), Liraglutide (Victoza), Tirzepatide (Mounjaro) | 1–2%+ | Significant loss (5–15%+) | CV benefit proven; now first-line for T2D with CVD or obesity |
| SGLT2 inhibitors | Empagliflozin (Jardiance), Dapagliflozin (Farxiga) | 0.5–1% | Mild loss | Strong kidney & heart failure protection; CV benefit |
| DPP-4 inhibitors | Sitagliptin (Januvia), Alogliptin | 0.5–0.8% | Neutral | Well-tolerated; no hypoglycemia; once daily |
| Sulfonylureas | Glipizide, Glimepiride | 1–1.5% | Weight gain | Inexpensive; long track record; risk of hypoglycemia |
| Pioglitazone (TZD) | Actos | 0.5–1.4% | Weight gain | Reduces CV events; beneficial in NASH; causes fluid retention |
| Insulin | Glargine, Detemir, Aspart, Lispro | Variable — very effective | Weight gain | Most powerful glucose-lowering; required in many patients |
2023 ADA guidance: For most patients with T2D and established cardiovascular disease or high CV risk, GLP-1 receptor agonists with proven CV benefit should be prioritized regardless of baseline HbA1c. For patients with heart failure or chronic kidney disease, SGLT2 inhibitors are preferred. Metformin remains first-line for most others.
| Insulin type | Onset | Peak | Duration | Use |
|---|---|---|---|---|
| Rapid-acting (Aspart, Lispro, Glulisine) | 10–20 min | 1–3 hr | 3–5 hr | Mealtime bolus — take just before eating |
| Ultra-rapid (Fiasp, Lyumjev) | 2–5 min | 1–2 hr | 3–5 hr | Can be taken at or after meals; useful with pumps |
| Regular (short-acting) | 30–60 min | 2–4 hr | 5–8 hr | Older formulation; used in IV drips in hospital |
| Intermediate-acting (NPH) | 1–2 hr | 4–12 hr | 14–24 hr | Less commonly used; twice daily; risk of hypoglycemia |
| Long-acting (Glargine, Detemir) | 1–2 hr | No pronounced peak | 20–24 hr | Once-daily basal insulin; backbone of T1D and many T2D regimens |
| Ultra-long-acting (Degludec) | 1 hr | No peak | 42+ hr | Once daily; very stable basal; lower hypoglycemia risk |
| Inhaled insulin (Afrezza) | 12–15 min | 30 min | 2–3 hr | Rapid-acting alternative for patients who prefer not to inject at meals |
GLP-1 drugs explained: Ozempic, Mounjaro, and beyond
GLP-1 receptor agonists have become the most talked-about class of drugs in medicine — and for good reason. They represent a fundamental advance in treating both diabetes and obesity.
How GLP-1 drugs work
GLP-1 (glucagon-like peptide-1) is a hormone naturally released by cells in the gut after eating. It has four key actions: it stimulates insulin secretion (only when blood sugar is elevated, minimizing hypoglycemia risk), suppresses glucagon (reducing liver glucose output), slows gastric emptying (reducing post-meal glucose spikes and promoting fullness), and acts on the brain's appetite centers to reduce hunger and food cravings.
| Drug (Brand) | Type | Dosing | HbA1c reduction | Average weight loss | CV benefit? |
|---|---|---|---|---|---|
| Semaglutide (Ozempic) | GLP-1 agonist | Weekly injection | ~1.5–2.0% | ~6–15% body weight | Yes (SUSTAIN-6) |
| Semaglutide (Wegovy) | GLP-1 agonist (higher dose) | Weekly injection | Primarily weight indication | ~15–17% | Yes (SELECT trial) |
| Tirzepatide (Mounjaro / Zepbound) | GLP-1 + GIP dual agonist | Weekly injection | ~2.0–2.4% | ~15–22% | Trial ongoing (SURPASS-CVOT) |
| Liraglutide (Victoza / Saxenda) | GLP-1 agonist | Daily injection | ~1.0–1.5% | ~5–8% | Yes (LEADER) |
| Semaglutide oral (Rybelsus) | GLP-1 agonist (oral) | Daily tablet | ~1.0–1.4% | ~3–4% | Neutral (SOUL trial) |
| Dulaglutide (Trulicity) | GLP-1 agonist | Weekly injection | ~1.1–1.6% | ~2–4% | Yes (REWIND) |
Common side effects and who should avoid GLP-1 drugs
The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — which typically occur early in treatment and improve as the dose is gradually escalated. Starting at the lowest dose and titrating slowly minimizes these effects.
GLP-1 drugs should generally be avoided in patients with: a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2); severe gastroparesis; or active pancreatitis. A history of pancreatitis requires careful consideration. Recent large studies have not confirmed a meaningful increase in pancreatic cancer risk with this drug class.
Rapid significant weight loss — from any cause — can lead to facial volume loss and a more aged appearance. This is not unique to semaglutide. The appropriate response is not to avoid effective treatment for a serious metabolic condition, but to discuss options with a healthcare provider if cosmetic concerns arise. Slower weight loss, adequate protein intake, resistance training, and facial filler procedures are all options patients may consider.
Nutrition and lifestyle for diabetes
There is no single "diabetic diet" — the evidence supports several dietary patterns, all of which share core principles: emphasizing whole foods, limiting ultra-processed foods and refined carbohydrates, and matching carbohydrate intake to individual metabolic capacity.
Dietary approaches with strong evidence
- Mediterranean diet: Olive oil, fish, vegetables, legumes, whole grains, nuts. The strongest overall evidence for cardiovascular risk reduction in diabetes. Allows moderate carbohydrate intake from high-quality sources.
- Low-carbohydrate diet (<130g carbs/day): Produces the largest short-term reductions in HbA1c and blood glucose of any dietary approach. Particularly effective for Type 2 diabetes — some patients achieve remission. Requires careful medication adjustment (especially insulin and sulfonylureas) to avoid hypoglycemia.
- Very low-calorie diet (800 kcal/day): Used in structured programs like the DiRECT trial to produce rapid weight loss and T2D remission. Not sustainable long-term; requires medical supervision.
- DASH diet: Reduces blood pressure — an important diabetes comorbidity. Moderate carbohydrate approach.
- Plant-based diets: Associated with lower T2D risk and improved glucose control. Adequate protein planning is important.
Physical activity
Exercise is a powerful glucose-lowering intervention. During aerobic exercise, muscles take up glucose independently of insulin — often reducing blood sugar significantly. The ADA recommends:
- 150+ minutes per week of moderate-intensity aerobic exercise (brisk walking, cycling, swimming)
- Resistance training 2–3 days per week
- Breaking up prolonged sitting every 30 minutes (even light movement reduces post-meal glucose spikes)
- Flexibility and balance training for older adults to prevent falls (neuropathy increases fall risk)
People with Type 1 diabetes and those on insulin need to monitor blood sugar carefully around exercise to prevent hypoglycemia — timing meals, adjusting doses, and sometimes having glucose sources available.
Diabetes technology
Continuous Glucose Monitors (CGM)
CGM systems use a small sensor inserted under the skin (typically on the arm or abdomen) that measures glucose in interstitial fluid every 5 minutes, transmitting readings to a smartphone or receiver. They have transformed diabetes management by revealing patterns invisible to fingerstick testing.
- Current leading systems: Dexcom G7, Abbott FreeStyle Libre 3, Medtronic Guardian 4
- Key metrics: Time in Range (TIR — % of readings 70–180 mg/dL), mean glucose, glucose variability (CV%), time below range, time above range
- Target TIR: >70% for most adults with diabetes; >50% for older or high-risk patients
- Now widely recommended for all Type 1 diabetes and many Type 2 patients using insulin
Insulin pumps and closed-loop systems
Insulin pumps deliver continuous subcutaneous insulin via a small catheter, eliminating the need for multiple daily injections. Modern hybrid closed-loop systems (also called "artificial pancreas") connect the pump to a CGM and use an algorithm to automatically adjust basal insulin delivery based on real-time glucose readings. Current leading systems include Tandem t:slim X2 with Control-IQ, Omnipod 5, and Medtronic MiniMed 780G. Clinical trials consistently show improved TIR, reduced hypoglycemia, and better quality of life compared to MDI or open-loop pumps.
Frequently asked questions
Type 1 is an autoimmune condition where the immune system destroys insulin-producing beta cells — requiring lifelong insulin therapy. It is not caused by diet or lifestyle and is not preventable. Type 2 is a progressive metabolic condition where cells become resistant to insulin and the pancreas can't compensate — managed initially with lifestyle changes and oral medications, though many patients eventually need insulin. Type 2 is strongly linked to obesity, inactivity, and genetics, and can often be prevented or put into remission with intensive lifestyle intervention.
Yes — significant weight loss (10–15% of body weight) through intensive dietary intervention or bariatric surgery can achieve remission of Type 2 diabetes in many patients, meaning normal blood sugar without medications. The DiRECT trial showed 46% of participants achieved remission at one year with a structured very low-calorie diet. GLP-1 receptor agonists also promote substantial weight loss and can facilitate remission. Remission is more likely in those with shorter duration of diabetes and less beta cell damage. Even if full remission isn't achieved, meaningful reduction in HbA1c and medication requirements is common.
Classic early symptoms include excessive thirst, frequent urination, unexplained weight loss, blurred vision, and fatigue. In Type 1, these symptoms can develop rapidly over days to weeks. In Type 2, symptoms often develop slowly over years — or are completely absent. Many people with Type 2 are diagnosed incidentally during routine blood tests. Tingling or numbness in the hands or feet (peripheral neuropathy) is sometimes the first noticed symptom in Type 2.
No — Ozempic (semaglutide) is a GLP-1 receptor agonist, a completely different class from insulin. It mimics the gut hormone GLP-1, stimulating insulin release only when blood sugar is elevated, suppressing glucagon, slowing gastric emptying, and reducing appetite. It cannot replace insulin for Type 1 diabetes (where the pancreas produces no insulin at all). When used alone (without insulin or sulfonylureas), it does not cause dangerous hypoglycemia — a significant advantage over many diabetes medications.
Diabetes is diagnosed by any of: fasting plasma glucose ≥126 mg/dL; 2-hour glucose ≥200 mg/dL during an oral glucose tolerance test; HbA1c ≥6.5%; or random glucose ≥200 mg/dL with classic symptoms. Prediabetes is fasting glucose 100–125 mg/dL or HbA1c 5.7–6.4%. A single abnormal result requires confirmation on a separate day — unless symptoms are present with a random glucose ≥200 mg/dL, which is sufficient for diagnosis alone.
- International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels, Belgium: IDF, 2021.
- American Diabetes Association. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1–S321.
- Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. NEJM. 2002;346(6):393–403.
- Lean MEJ, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT). Lancet. 2018;391(10120):541–551.
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM. 2016;375:1834–1844.
- Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). NEJM. 2015;373:2117–2128.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022;387:205–216.